Disease Description
Melanoma is considered the most dangerous form of skin cancer. These cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumors. These tumors originate in cells called melanocytes. Melanocytes are the cells responsible for giving our skin their color. Melanomas often resemble moles; some develop from moles. The majority of melanomas are black or brown, but they can also be skin-colored, pink, red, purple, blue or white. Melanoma is caused mainly by intense, occasional UV light exposure (frequently leading to sunburn), especially in those who are genetically predisposed to the disease. [1]
Prevelance
Melanoma is the fifth most common cancer in men and seventh in women in the United States. The number of melanoma cases is increasing faster than for any other type of cancer. Estimates for 2014 are that 76,100 invasive melanomas will be diagnosed in the United States and that melanoma could claim 9710 lives [2].
Current Treatment Options
At present, prevention and early detection are the only effective measures against melanoma. Melanoma basically remains a surgical disease, and excision of thin, biologically early tumors offers the best chance of cure. Despite intensive research, no effective therapies exist for advanced melanoma. Only high-dose IFN -2b has a reproducible benefit in stage II and III patients, but owing to its numerous side effects, modest efficacy, and high cost, it is not used worldwide and is inconsistently used in the United States. For patients with stage IV melanoma, randomized, controlled trials have shown no significant advantage of any specific drug or combination of drugs. Dacarbazine, the only cytotoxic drug approved by the FDA for the treatment of metastatic melanoma, remains the benchmark, but it produces responses of moderate duration and only in a small fraction of the patients. New therapeutic strategies are therefore necessary for the management of melanomas.[3]
Evidence for and the Proposed Mechanism of Cannabinoid Therapeutics
Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Cannabinoids were also reported to inhibit the growth of melanomas that express cannabinoid receptors (CB1 and CB2) by decreasing growth, proliferation, blood vessel growth and metastasis formation, while increasing cell death. [4]
Groups have studied the potential efficacy of cannabinoids as antitumoral agents against melanoma and showed that these compounds exert a remarkable growth-inhibiting effect on melanoma cells that is evident under various experimental settings (animals with different immune statuses, melanoma cells inoculated at different sites, cannabinoids injected by different routes). Moreover, this is associated with an improvement of various tumor-progression parameters (decreased proliferation and vascularization, increased cell death), as well as with an inhibition of tumor-cell metastatic spreading, one of the clinical hallmarks of advanced melanoma.[5]
Together with the implication of cannabinoid receptors (CB2) in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects. Specifically, the antiproliferative effect of cannabinoids reported may set the basis for a new therapeutic approach for the treatment of malignant melanoma.[5]
1. Skin Cancer Foundation. www.skincancer.org/
2. National Cancer Institute. http://seer.cancer.gov/statfacts/html/melan.html
3. Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
4. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.
5.Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Can you advise us as to when the original CBIS stock will be converted and what will the new stock be listed under - its ticker symbol.
Good Afternoon, Guys! Do we EVER have an Update for you, as stated earlier, 2024 is our Year! We are in the process of closing a couple of new...Good Afternoon, Guys! Do we EVER have an Update for you, as stated earlier, 2024 is our Year! We are in the process of closing a couple of new Partnership deals for Cannabis Science and our Expedited cancer drug development program. We are still working on the paperwork, but we can certainly start Thanking God now! That is for sure! We will be putting News Releases out in each respective Public Company and continue our FDA quest for an IND# so we can start Phase 1 Clinical Studies for Killing these Nasty Cancers.
As mentioned earlier, we will shut down the CSi-VIP Legacy Drug Ownership Program as soon as we close the first deal, the paperwork is forthcoming. We are still working on the investment reports for ALL our CSi-VIPs as stated, so you still have time to purchase your personal share of the CSi-Legacy Cancer Drug! It has certainly been a long time coming!
If you are NOT a CSi-VIP and you are interested in directly owning a piece of our CSi-Legacy Drug, it’s NOT too late for you either!
The CSi-VIP Legacy Drug Ownership Program links are all Live and updated, if you have any questions, Please feel free to contact me directly for ALL your options available this week.
*** Send me an email with your questions and contact info.
raymond.dabney@cannabisscience.com
Ps … For ALL of you sending emails “feeling off” about our continuous CSi-VIP Gifts and Offerings. Maybe you will be more comfortable if we start selling some of our own Shiny Sneakers, Bibles, Bobbleheads, NFTs, Coins, Hats, Socks, Coffee Mugs, Stickers, Calendars, Inflatable Pool Toys, Trading Cards, Toilet Paper, a Hat with MY Hair, Posters, Signed Autographs, Chia Pet Head, Flags, Clocks, Pins, and I’m sure we can come up with many more creative Fun Items. So, in the near Future, we will open our own “1 Million Strong-CSi-iCannabinoid-ASU Gift Shop” for EVERYONE to take your pick of our own Branded Merchandise for your enjoyment and specialty items collection.
*** Right now, with our CSi-VIP offerings, you Only need to KNOW that ALL your funding is going towards the continuous Successful operations required to bring our “Low-Cost, CSi-Cancer Killing Drugs” to market ASAP. You are a BIG part of the Key to Make that Change. So, let’s make sure you are a CSi-Legacy Drug Owner before that door closes too, that is the Best I can say, for now.
Good Bless us ALL.
Talk soon Guys.
Raymond - IGWT
raymond.dabney@cannabisscience.com
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Hey Mike good morning! Hope all is well for you! Sorry for the delayed response I know this is your second poke! Once... Show more 1 week ago